RxDoctor Payments Data

Terry Holster, MD

Internal Medicine · Sugar Land, TXNPI 1326087040

Payments from drug & device makers

$6,469in general payments, 2019–2025

Across 327 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$903
  • Amarin Pharma, Inc.$428
  • AstraZeneca$425
  • Antares Pharma, Inc.$296
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$6,40499%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,469 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$72,518
Medicare patients
252
Services billed
978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$167,638
MounjaroTirzepatide114$114,337
EliquisApixaban78$56,301
JanuviaSitagliptin Phosphate58$46,892
TrulicityDulaglutide47$44,661
Humalog Kwikpen U-200Insulin Lispro17$34,531
MyrbetriqMirabegron47$29,460
XareltoRivaroxaban28$27,886
Repatha SureclickEvolocumab39$25,379
VascepaIcosapent Ethyl45$22,553
FarxigaDapagliflozin Propanediol14$19,293
Xultophy 100-3.6Insulin Degludec/Liraglutide12$18,357
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,531
RybelsusSemaglutide15$12,739
SynthroidLevothyroxine Sodium112$10,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus$1,051$198,734163 claims
Lilly USA, LLCMounjaro, Trulicity$903$158,997161 claims
PfizerEliquis, Paxlovid$238$57,731104 claims
MerckJanuvia, Belsomra$113$55,62172 claims
Astellas Pharma US IncMyrbetriq$66$29,46047 claims
Johnson & JohnsonXarelto$50$27,88628 claims
AbbVieSynthroid, Linzess$128$20,171125 claims
AstraZenecaFarxiga$425$19,29314 claims
GSKTrelegy Ellipta$187$16,53118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →